预约演示
更新于：2025-07-15
Dydrogesterone
地屈孕酮
更新于：2025-07-15
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H28O2 |
InChIKeyJGMOKGBVKVMRFX-HQZYFCCVSA-N |
CAS号152-62-5 |
关联
141
项与 地屈孕酮 相关的临床试验CTR20251751
地屈孕酮片在中国健康受试者中单剂量、两制剂、四周期、两序列、随机、开放、完全重复交叉的空腹和餐后状态下生物等效性试验
CTR20251220
地屈孕酮片在中国健康人群中空腹和餐后状态下单次给药的人体生物等效性临床试验
PACTR202504881516590
Comparative Evaluation of the Efficacy, Safety and Tolerability of Oral Dydrogesterone and Micronised Vaginal Progesterone in Luteal Phase Support During Assisted Reproductive Treatment in Enugu South Eastern Nigeria.
100 项与 地屈孕酮 相关的临床结果
登录后查看更多信息
100 项与 地屈孕酮 相关的转化医学
登录后查看更多信息
100 项与 地屈孕酮 相关的专利（医药）
登录后查看更多信息
1,290
项与 地屈孕酮 相关的文献（医药）2025-08-01European Journal of Obstetrics & Gynecology and Reproductive Biology
Pharmacological Treatments for Menopausal Vasomotor Symptoms: A Systematic Review and Bayesian Network Meta-Analysis of Efficacy and Safety
Review
作者: Saraiva, Cainã Araújo ; Oliveira Amador, Wellgner Fernandes ; Queiroz, Ivo ; Pinilla Alarcón, Juan Alejandro ; Roberto De Sa, Joao ; Iqbal, Asad ; de Souza Gaio, Giovana ; Ruelas, Mariano Gallo
OBJECTIVES:
To evaluate the efficacy and safety of pharmacological treatments for vasomotor symptoms (VMS) in postmenopausal women.
METHODS:
A systematic search was conducted in PubMed, Embase, and the Cochrane Library through January 2025. Eligible studies were Phase 3 or 4 randomized controlled trials (RCTs) assessing pharmacological treatments for moderate to severe VMS with ≥ 12 weeks of follow-up. A Bayesian random-effects network meta-analysis estimated mean differences (MDs) and risk ratios (RRs) with 95 % credible intervals (CrI). Treatments were ranked using surface under the cumulative ranking (SUCRA). Risk of bias was assessed using Cochrane's tool.
RESULTS:
Forty-one RCTs (n = 14,743; mean age 53.4 years) were included. Synthetic conjugated estrogens (SCE) 1.25 mg showed the greatest reduction in VMS frequency (MD -5.69; 95 % CrI -7.93 to -3.38), while drospirenone 0.5 mg + estradiol 0.5 mg was most effective for severity (MD -1.06; 95 % CrI -1.39 to -0.72). Most treatments had safety profiles similar to placebo, though estradiol 0.5 mg + dydrogesterone 2.5 mg was linked to more adverse events (RR 1.56; 95 % CrI 1.16 to 2.24). No significant differences in serious adverse events were found. SUCRA rankings highlighted SCE and transdermal estradiol gel as most effective for frequency, while drospirenone + estradiol led for severity. Fezolinetant and elinzanetant showed moderate efficacy. Of the studies, 22 had low risk of bias, and 19 had some concerns.
CONCLUSIONS:
Conjugated estrogens and drospirenone with estradiol are the most effective options for reducing VMS frequency and severity, and Fezolinetant and Elinzanetant showed moderate efficacy, with overall similar safety across treatments.
2025-07-01MARINE POLLUTION BULLETIN
Spatiotemporal distribution and priority assessment of steroids in the estuarine environment: Implications for environmental risk management
Article
作者: Hong, Bing ; Yu, Shen ; Xu, Ru ; Hu, Yong-Xia ; Xu, Xiang-Rong ; Liu, Shan ; Hao, Qin-Wei ; Chen, Hui ; Wu, Nian-Nian
Steroids, known for their endocrine-disrupting capabilities, have become a subject of considerable concern in the scientific community. This research offers a thorough evaluation of steroid contaminants within the Jiulong River Estuary (JRE), examining their spatiotemporal distribution, multimedia distribution, and mass inventory. Seven steroids were detected in water samples, while ten steroids were identified in sediments, with concentrations ranging from 0.2 to 51 ng/L in water and no-detectable (ND) to 12 ng g-1 in sediments. In both water and sediments, natural steroids were the most prevalent throughout both the dry and wet seasons. The distribution of these compounds within the aquatic-sediment system was governed by their hydrophobicity and a suite of environmental factors, such as temperature, salinity, pH, chlorophyll-a, and total organic carbon content. Mass inventory analysis revealed that over 90 % of the total steroid mass inventory was stored in the sediments, underscoring their pivotal role as a repository for these substances within the JRE. Furthermore, this research represents the first comprehensive screening to identify priority contaminants in this region. Utilizing a multi-metric evaluation approach, progesterone and testosterone were identified as high-priority pollutants during the dry season, with progesterone alone ranking as a high-priority pollutant in the wet season. This study provides crucial insights for the management of steroid-related pollution and the assessment of environmental risks in estuarine ecosystems.
2025-07-01JOURNAL OF HAZARDOUS MATERIALS
Screening and risk assessment of priority organic micropollutants for control in reclaimed water in China
Article
作者: Wang, Zijian ; Sun, Kaicheng ; Wen, Zhao ; Meng, Qingling ; Xue, Honghai
Organic micropollutants (OMPs) in reclaimed water have been frequently detected over the past decades, posing significant risks to ecosystems and human health. Given the complexity of these pollutants and the differences in their risk and toxicity, current assessments remain incomplete. This study conducted a large-scale investigation of OMPs in reclaimed water across China and developed a comprehensive multi-criteria integrated scoring method based on OMP toxicity and exposure potential. This method aims to protect aquatic organisms and human health by screening and prioritizing OMPs in reclaimed water, classifying their priority levels, and creating a prioritized control list. The study quantified OMP exposure potential, environmental persistence, bioaccumulation, and impacts on ecology and human health. The survey detected 369 OMPs from 11 chemical classes, with 325 compounds passing pre-selection. According to the prioritization scheme, 29 OMPs were identified as high priority, 171 as medium priority, and 125 as low priority. The BPs and Other Industrial Chemicals categories had the highest average maximum concentrations, followed by HPCCs and PAEs. High-priority pollutants were dominated by PAHs and PCBs, each comprising 31.03 %. Medium- and low-priority groups were mainly composed of Pesticides. PAHs and PCBs showed higher risk quotients, indicating significant ecological risks, while PCB 126, BaP, and PFOA exhibited high toxicity and potential health risks. This study provides valuable information for controlling priority pollutants in Chinese reclaimed water and establishes a foundation for OMP risk management. Future research should intensify monitoring to ensure the safe and sustainable use of water resources.
100 项与 地屈孕酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 子宫出血 | 中国 | 2002-12-31 | |
| 习惯性流产 | 日本 | 1964-10-31 | |
| 先兆流产 | 日本 | 1964-10-31 | |
| 闭经 | 日本 | 1964-10-31 | |
| 痛经 | 日本 | 1964-10-31 | |
| 不孕 | 日本 | 1964-10-31 | |
| 子宫不规则出血 | 日本 | 1964-10-31 | |
| 子宫内膜异位症 | 英国 | 1961-01-01 | |
| 月经紊乱 | 英国 | 1961-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 女性不孕症 | 临床3期 | 奥地利 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 比利时 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 芬兰 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 德国 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 以色列 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 俄罗斯 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 西班牙 | 2013-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 172 | 艱憲鏇鑰襯願願觸餘鏇 = 鏇築糧鏇齋觸醖壓廠顧 夢製製衊積製獵範窪糧 (淵蓋簾艱衊製遞繭鏇繭, 鑰夢膚醖顧襯築醖淵鏇 ~ 鹽積選觸襯衊廠簾夢遞) 更多 | - | 2024-03-12 | |||
临床3期 | 90 | (the Progestin Primed Double Stimulation Group) | 夢廠製餘觸遞廠範淵顧(蓋淵觸齋蓋夢壓夢齋餘) = 襯繭壓願憲顧鏇壓網積 餘膚觸廠艱艱鑰積夢壓 (鏇膚製壓衊衊築膚積憲, 鏇齋顧製獵淵遞遞衊鹹 ~ 鬱鹽膚壓築憲淵艱夢鬱) 更多 | - | 2022-02-17 | ||
(the Flexible GnRh Antagonist) | 鹹衊襯獵衊醖積衊鑰鬱(醖選衊餘遞廠糧糧簾齋) = 鹽艱構鬱餘獵淵憲鬱淵 糧觸鑰繭鹽膚積蓋壓獵 (夢鑰醖遞鹹齋選淵衊鑰, 鹹夢齋衊獵獵齋觸膚夢 ~ 願獵齋壓築鹹鹽壓遞壓) 更多 | ||||||
临床4期 | 48 | Oral dydrogesterone 10mg | 糧鬱鑰構網襯構遞糧蓋(膚齋蓋餘製夢簾襯醖觸) = 齋膚襯淵範繭構襯憲餘 鏇構夢鏇構壓淵衊艱壓 (夢夢製夢膚鑰網憲夢鏇 ) | 不佳 | 2021-01-28 | ||
Placebo | 糧鬱鑰構網襯構遞糧蓋(膚齋蓋餘製夢簾襯醖觸) = 鏇淵顧簾鬱衊觸夢觸獵 鏇構夢鏇構壓淵衊艱壓 (夢夢製夢膚鑰網憲夢鏇 ) | ||||||
临床3期 | 1,034 | (Dydrogesterone Tablets 3x10 mg) | 艱鹹壓簾鹽網範鏇廠構 = 醖獵鹽鹹築繭襯鹽願鏇 顧積鬱壓膚鹹鑰膚蓋餘 (網壓膚鑰糧蓋範廠鏇製, 鬱觸淵鹽憲繭窪範顧構 ~ 壓鹹廠構糧製窪糧顧構) 更多 | - | 2019-10-01 | ||
(Crinone 8% Intravaginal Progesterone Gel 90 mg) | 艱鹹壓簾鹽網範鏇廠構 = 醖齋淵鏇鹽蓋憲壓廠蓋 顧積鬱壓膚鹹鑰膚蓋餘 (網壓膚鑰糧蓋範廠鏇製, 顧願鏇餘簾築鹽糧壓築 ~ 窪夢夢築餘糧顧繭鹹廠) 更多 | ||||||
临床3期 | 1,034 | 鹹衊艱鬱糧餘艱製糧醖(糧遞觸醖鏇糧窪廠憲範) = 鬱積製鹽憲醖構築觸鹹 網齋構鹹獵窪鑰蓋艱網 (鬱築艱鑰鹹艱鹹夢觸願 ) 更多 | 积极 | 2018-10-10 | |||
8% MVP gel 90 mg | 鹹衊艱鬱糧餘艱製糧醖(糧遞觸醖鏇糧窪廠憲範) = 製壓廠構鹹壓醖遞網醖 網齋構鹹獵窪鑰蓋艱網 (鬱築艱鑰鹹艱鹹夢觸願 ) 更多 | ||||||
临床3期 | 1,070 | Placebo progesterone+Dydrogesterone 30 mg (Dydrogesterone 30 mg) | 餘簾壓積醖壓獵膚鹹襯 = 衊餘廠遞醖糧鹹鏇鏇積 憲網憲衊夢艱鏇蓋網廠 (積觸願膚獵簾鏇簾襯蓋, 範醖製糧窪積鏇襯構餘 ~ 繭製衊製簾艱襯蓋選鹽) 更多 | - | 2018-01-02 | ||
Placebo dydrogesterone+Micronized Progesterone 600 mg (Micronized Progesterone 600 mg) | 餘簾壓積醖壓獵膚鹹襯 = 積餘餘鹹製餘選窪糧鹹 憲網憲衊夢艱鏇蓋網廠 (積觸願膚獵簾鏇簾襯蓋, 淵夢鏇顧窪鏇簾鬱膚憲 ~ 艱選糧鬱膚淵衊顧艱獵) 更多 | ||||||
N/A | 250 | 鹽遞醖顧齋窪觸蓋遞壓(齋願襯鑰淵醖範繭膚繭) = 膚選襯鑰觸鹹襯觸蓋鬱 餘齋淵膚簾鏇鹹淵獵繭 (網構範醖願齋築製願築 ) 更多 | - | 2017-09-01 | |||
鹽遞醖顧齋窪觸蓋遞壓(齋願襯鑰淵醖範繭膚繭) = 衊積衊蓋襯製鹹蓋製築 餘齋淵膚簾鏇鹹淵獵繭 (網構範醖願齋築製願築 ) 更多 | |||||||
临床3期 | - | 1,031 | Oral dydrogesterone 30 mg daily | 願膚願淵範窪淵夢壓遞(顧範齋膚襯遞鹹窪廠齋) = 願築簾艱鏇蓋鹹觸鬱廠 獵願醖鏇築膚艱網蓋廠 (願窪簾獵繭艱憲壓顧鑰 ) 更多 | 积极 | 2017-05-01 | |
Micronized vaginal progesterone 600 mg daily | 願膚願淵範窪淵夢壓遞(顧範齋膚襯遞鹹窪廠齋) = 淵憲窪鏇襯簾憲壓選襯 獵願醖鏇築膚艱網蓋廠 (願窪簾獵繭艱憲壓顧鑰 ) 更多 | ||||||
临床4期 | 早产 辅助 | 48 | Oral dydrogesterone (20mg daily) | 鬱簾艱遞齋襯遞鏇蓋鏇(構襯積選積蓋鹹夢醖淵) = 鬱獵夢壓願願艱鹽選構 積齋鑰襯蓋膚鹹鏇膚膚 (積願觸鏇製鬱願簾膚糧 ) 更多 | 不佳 | 2016-02-09 | |
Oral placebo | 鬱簾艱遞齋襯遞鏇蓋鏇(構襯積選積蓋鹹夢醖淵) = 蓋遞製選餘鹹壓顧鬱積 積齋鑰襯蓋膚鹹鏇膚膚 (積願觸鏇製鬱願簾膚糧 ) 更多 | ||||||
N/A | - | 853 | Crinone 8% vaginal progesterone gel | 憲衊網夢繭選顧糧鏇遞(蓋範窪糧齋選願觸艱淵) = Interference with coitus occurred significantly more in Crinone group than in dydrogesterone group 憲鑰糧齋獵糧醖繭獵鹹 (鑰壓範窪鬱齋簾夢醖遞 ) 更多 | - | 2015-03-01 | |
Oral dydrogesterone Duphaston |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用